Patents by Inventor John Van Duzer
John Van Duzer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220008445Abstract: Provided herein are methods of treating an ocular disease associated with one or more nonsense mutation in a subject using one or more amino-glycosides and/or derivatives thereof. The pharmaceutical compositions and kits containing one or more aminoglycosides and/or derivatives thereof for treating the ocular disease are disclosed.Type: ApplicationFiled: November 27, 2019Publication date: January 13, 2022Inventors: John VAN DUZER, Greg WILLIAMS
-
Publication number: 20130189218Abstract: The invention described herein provides a mixture comprising polymer molecules or salts thereof, wherein a polymer molecule in the mixture comprises covalently bound subunits L, K, and M wherein the average molecular weight of the polymer molecules in the mixture is about 50 kDa to about 200 kDa, wherein the mole percentage of subunit M, K and L, relative to the total amount of subunits in the mixture, is about 90.5 to about 96 mol %, about 2.8 to about 7.3 mol %, and about 1.2 to about 2.2 mol %, respectively.Type: ApplicationFiled: December 21, 2012Publication date: July 25, 2013Applicant: Mersana Therapeutics, Inc.Inventors: Laura Akullian, Gui Liu, Timothy B. Lowinger, Dennis McGillicuddy, Cheri Stevenson, John Van Duzer, Mao Yin, Aleksandr Yurkovetskiy
-
Publication number: 20080027060Abstract: N-terminal substituted dipeptide nitriles as defined are useful as inhibitors of cysteine cathepsins, e.g. cathepsins B, K, L and S, and can be used for the treatment of cysteine cathepsin dependent diseases and conditions, including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis, tumors (especially tumor invasion and tumor metastasis), coronary disease, atherosclerosis (including atherosclerotic plaque rupture and destabilization). Particular dipeptide nitriles are compounds of formula I, or physiologically-acceptable and -cleavable esters or a salts thereof wherein: the symbols are as defined. In particular it has been found that by appropriate choice of groups R, R2, R3, R4, R5, X1, Y and L, the relative selectivity of the compounds as inhibitors of the various cysteine cathepsin types, e.g. cathepsins B, K, L and S may be altered, e.g. to obtain inhibitors which selectively inhibit a particular cathepsin type or combination of cathepsin types.Type: ApplicationFiled: August 7, 2007Publication date: January 31, 2008Inventors: Eva Altmann, Claudia Betschart, Keigo Gohda, Miyuki Horiuchi, Rene Lattmann, Martin Missbach, Junichi Sakaki, Michihiro Takai, Naoki Teno, Scott Cowen, Paul Greenspan, Leslie McQuire, Ruben Tommasi, John van Duzer
-
Publication number: 20070238747Abstract: The present invention features rifamycin analogs that can be used as therapeutics for treating or preventing a variety of microbial infections. In one form, the analogs are acetylated at the 25-position, as is rifamycin. In another form, the analogs are deacetylated at the 25-position. In yet other forms, benzoxazinorifamycin, benzthiazinorifamycin, and benzdiazinorifamycin analogs are derivatized at various positions of the benzene ring, including 3?-hydroxy analogs, and/or various fused ring systems with the benzene ring at the 4?,5? or 5?,6? positions.Type: ApplicationFiled: May 17, 2007Publication date: October 11, 2007Applicant: ActivBiotics, Inc.Inventors: John van Duzer, Arthur Michaelis, William Geiss, Douglas Stafford, Xiang Yu, James Siedlecki, Yingfei Yang
-
Publication number: 20070155715Abstract: The present invention features rifamycin analogs and methods of using these compounds to treat a variety of microbial infections.Type: ApplicationFiled: December 14, 2006Publication date: July 5, 2007Applicant: ActivBiotics, Inc.Inventors: John van Duzer, Arthur Michaelis, William Geiss, Douglas Stafford, Joseph Raker, Xiang Yu, James Siedlecki, Yingfei Yang
-
Publication number: 20070105849Abstract: The present invention features rifamycin analogs that can be used as therapeutics for treating or preventing a variety of microbial infections. In one form, the analogs are acetylated at the 25-position, as is rifamycin. In another form, the analogs are deacetylated at the 25-position. In yet other forms, benzoxazinorifamycin, benzthiazinorifamycin, and benzdiazinorifamycin analogs are derivatized at various positions of the benzene ring, including 3?-hydroxy analogs, 5?-halo and/or alkoxy analogs, and various 4?- and/or 6?-substituents that incorporate a cyclic amine moiety.Type: ApplicationFiled: November 2, 2006Publication date: May 10, 2007Applicant: ActivBiotics, Inc.Inventors: John Van Duzer, James Siedlecki, Xiang Yu
-
Patent number: 7135491Abstract: The present invention relates to 5-Aryltetrazole Compounds, compositions comprising an effective amount of a a 5-Aryltetrazole Compound, and methods for treating an inflammation disease, a reperfusion disease, or hyperuricemia in an animal in need thereof comprising administering to the animal an effective amount of a 5-Aryltetrazole compound.Type: GrantFiled: January 6, 2005Date of Patent: November 14, 2006Assignee: Inotek Pharmaceuticals Corp.Inventors: Alex Nivorozhkin, John Van Duzer, Andrew Salzman, Garry Southan, Siya Ram, Qi Zeng, Csaba Szabo
-
Patent number: 7087631Abstract: The present invention relates to 5-Aryltetrazole Compounds, compositions comprising an effective amount of a 5-Aryltetrazole Compound, and methods for treating an inflammation disease, a reperfusion disease, or hyperuricemia in an animal in need thereof comprising administering to the animal an effective amount of a 5-Aryltetrazole compound.Type: GrantFiled: July 17, 2003Date of Patent: August 8, 2006Assignee: Inotek Pharmaceuticals CorporationInventors: Alex Nivorozhkin, John Van Duzer, Garry Southan, Siya Ram, Qi Zeng
-
Patent number: 7078423Abstract: The present invention relates to 5-Aryltetrazole compounds, compositions comprising a 5-Aryltetrazole compound, and methods for treating an inflammation disease, a reperfusion disease, hyperuricemia, gout, or tumor-lysis syndrome in an animal in need thereof comprising administering to the animal an effective amount of a 5-Aryltetrazole compound.Type: GrantFiled: July 18, 2002Date of Patent: July 18, 2006Assignee: Inotek Pharmaceuticals CorporationInventors: Alex Nivorozhkin, John Van Duzer, Andrew Salzman, Garry Southan, Siya Ram, Qi Zeng, Csaba Szabo
-
Publication number: 20060135519Abstract: Abstract of the Disclosure ABSTRACT5-ARYLTETRAZOLES COMPOUNDS AND COMPOSITIONS THEREOFThe present invention relates to 5-Aryltetrazole Compounds, compositions comprising an effective amount of a 5-Arytetrazole Compound, and methods for treating an inflammation disease, a reperfusion disease, or hyperuricemia in an animal in need thereof comprising administering to the animal an effective amount of a 5-Aryltetrazole compound.Type: ApplicationFiled: January 6, 2005Publication date: June 22, 2006Inventors: Alexander NIVOROZHKIN, John VAN DUZER, Garry SOUTHAN, Siya RAM, Qi ZENG
-
Publication number: 20050228007Abstract: The present invention relates to Isoquinoline Derivatives, compositions comprising an effective amount of a Isoquinoline Derivative and methods for treating or preventing an inflammatory disease, a reperfusion injury, an ischemic condition, renal failure, diabetes, a diabetic complication, a vascular disease other than a cardiovascular disease, cardiovascular disease, reoxygenation injury resulting from organ transplantation, Parkinson's disease, or cancer, comprising administering to an animal in need thereof an effective amount of a Isoquinoline Derivative.Type: ApplicationFiled: February 25, 2005Publication date: October 13, 2005Inventors: Prakash Jagtap, Erkan Baloglu, John Van Duzer, Csaba Szabo, Andrew Salzman, Aloka Roy, William Williams, Alexander Nivorozhkin
-
Publication number: 20050197333Abstract: The present invention features rifamycin analogs that can be used as therapeutics for treating or preventing a variety of microbial infections. In one form, the analogs are acetylated at the 25-position, as is rifamycin. In another form, the analogs are deacetylated at the 25-position. In yet other forms, benzoxazinorifamycin, benzthiazinorifamycin, and benzdiazinorifamycin analogs are derivatized at various positions of the benzene ring, including 3?-hydroxy analogs, 4?- and/or 6? halo and/or alkoxy analogs, and various 5? substituents that incorporate a cyclic amine moiety.Type: ApplicationFiled: December 22, 2004Publication date: September 8, 2005Inventors: John van Duzer, Arthur Michaelis, William Geiss, Douglas Stafford, Joseph Raker, Xiang Yu, James Siedlecki, Yingfei Yang
-
Publication number: 20050159467Abstract: The present invention relates to 5-Aryltetrazole Compounds, compositions comprising an effective amount of a a 5-Aryltetrazole Compound, and methods for treating an inflammation disease, a reperfusion disease, or hyperuricemia in an animal in need thereof comprising administering to the animal an effective amount of a 5-Aryltetrazole compound.Type: ApplicationFiled: January 6, 2005Publication date: July 21, 2005Inventors: Alex Nivorozhkin, John Van Duzer, Andrew Salzman, Garry Southan, Siya Ram, Qi Zeng, Csaba Szabo
-
Publication number: 20050159418Abstract: The present invention relates to 5-Aryltetrazole Compounds, compositions comprising an effective amount of a a 5-Aryltetrazole Compound, and methods for treating an inflammation disease, a reperfusion disease, or hyperuricemia in an animal in need thereof comprising administering to the animal an effective amount of a 5-Aryltetrazole compound.Type: ApplicationFiled: January 6, 2005Publication date: July 21, 2005Inventors: Alex Nivorozhkin, John Van Duzer, Garry Southan, Siya Ram, Qi Zeng
-
Publication number: 20050137189Abstract: The present invention features rifamycin analogs that can be used as therapeutics for treating or preventing a variety of microbial infections. In one form, the analogs are acetylated at the 25-position, as is rifamycin. In another form, the analogs are deacetylated at the 25-position. In yet other forms, benzoxazinorifamycin, benzthiazinorifamycin, and benzdiazinorifamycin analogs are derivatized at various positions of the benzene ring, including 3?-hydroxy analogs, and/or various fused ring systems with the benzene ring at the 4?,5? or 5?,6? positions.Type: ApplicationFiled: December 9, 2004Publication date: June 23, 2005Inventors: John van Duzer, Arthur Michaelis, William Geiss, Douglas Stafford, Xiang Yu, James Siedlecki, Yingfei Yang
-
Publication number: 20050049270Abstract: The invention provides novel classes of Isoquinoline Derivatives. Pharmaceutical compositions and methods of making and using the compounds, are also described.Type: ApplicationFiled: October 12, 2004Publication date: March 3, 2005Inventors: Prakash Jagtap, Erkan Baloglu, John van Duzer, Csaba Szabo, Andrew Salzman, Aloka Roy, William Williams, Alexander Nivoroshkin
-
Publication number: 20050043298Abstract: The present invention features rifamycin analogs that can be used as therapeutics for treating or preventing a variety of microbial infections. In one form, the analogs are acetylated at the 25-position, as is rifamycin. In another form, the analogs are deacetylated at the 25-position. In yet other forms, benzoxazinorifamycin, benzthiazinorifamycin, and benzdiazinorifamycin analogs are derivatized at various positions of the benzene ring, including 3?-hydroxy analogs, 4?-and/or 6? halo and/or alkoxy analogs, and various 5? substituents that incorporate a cyclic amine moiety.Type: ApplicationFiled: August 11, 2004Publication date: February 24, 2005Inventors: John van Duzer, Arthur Michaelis, William Geiss, Douglas Stafford, Joseph Raker
-
Publication number: 20040116423Abstract: The present invention relates to 5-Aryltetrazole Compounds, compositions comprising an effective amount of a a 5-Aryltetrazole Compound, and methods for treating an inflammation disease, a reperfusion disease, or hyperuricemia in an animal in need thereof comprising administering to the animal an effective amount of a 5-Aryltetrazole compound.Type: ApplicationFiled: July 17, 2003Publication date: June 17, 2004Inventors: Alex Nivorozhkin, John Van Duzer, Andrew Salzman, Garry Southan, Siya Ram, Qi Zeng, Csaba Szabo
-
Publication number: 20040019208Abstract: The present invention relates to 5-Aryltetrazole compounds, compositions comprising a 5-Aryltetrazole compound, and methods for treating an inflammation disease, a reperfusion disease, hyperuricemia, gout, or tumor-lysis syndrome in an animal in need thereof comprising administering to the animal an effective amount of a 5-Aryltetrazole compound.Type: ApplicationFiled: July 18, 2002Publication date: January 29, 2004Inventors: Alex Nivorozhkin, John Van Duzer, Andrew Salzman, Garry Southan, Siya Ram, Qi Zeng, Csaba Szabo